HEALTH● LOWJul 2 · Jul 2, 2026, 6:20 PM
Novartis gene therapy Itvisma approved in EU for spinal muscular atrophy
Seeking Alpha Tech
Novartis's gene therapy, Itvisma, has received approval in the European Union for the treatment of spinal muscular atrophy. This marks a significant development in available treatments for the condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH45m agoMore workers are skipping doctor's visits over money worriesCBS NewsHEALTH1h agoLetter : Utah should invest in student mental healthsltrib.com · United StatesHEALTH1h agoNCDs fastest-growing disease burden in Nigeria — OfficialPremium TimesHEALTH2h agoFG ‘revitalises’ 4,434 PHCs, expands access to quality healthcare servicesPremium Times